ADMIRAL analysis: survival by mutation status in gilteritinib-treated FLT3+ R/R AML

Mark Levis, MD, PhD, from the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, discusses the analysis of ADMIRAL trial (NCT02421939) data. Dr Levis discusses how in this study, which investigated gilteritinib in FLT3+ relapsed/refractory acute myeloid leukemia (AML), survival was prolonger in patients with common AML co-mutations or a high FLT3-ITD allelic ration. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.